Please login to the form below

Afinitor

This page shows the latest Afinitor news and features for those working in and with pharma, biotech and healthcare.

some big sellers like cancer drug Afinitor and Gilenya for multiple sclerosis in 2019, according to a report on aktiencheck.de.

AAA board presses go on $3.9bn Novartis takeover

Novartis has no heritage in this type of medicine but already markets two drugs for NET – Sandostatin (octreotide) and Afinitor/Votubia (everolimus) – so the acquisition makes sense from a franchise perspective, ... Latterly Sandostatin has played
NICE gives green light to Ipsen's Cabometyx

Earlier this year NICE performed a similar U-turn on Novartis’kidney cancer drug Afinitor, following an offer of discount earlier and the provision of new evidence.
NICE U-turn on Novartis' Afinitor for kidney cancer

NICE U-turn on Novartis' Afinitor for kidney cancer. Set to back treatment's routine NHS use following offer of discount and new data. ... The UK's National Institute for Health and Care Excellence (NICE) has reversed its previous ruling on Afinitor and
NICE backs Novartis' Afinitor and Pfizer's Xalkori

NICE backs Novartis' Afinitor and Pfizer's Xalkori. Provisionally approves breast and lung cancer drugs after greater discounts offered. ... NICE has provisionally recommended Novartis' Afinitor and Pfizer's Xalkori for routine use on the NHS in breast
NICE U-turn on Opdivo for kidney cancer

In a phase III clinical study, patients treated with Opdivo lived for an average of 5.4 months longer than the group who received Novartis' Afinitor (everolimus), the standard therapy, and

More from news
Approximately 13 fully matching, plus 64 partially matching documents found.

Back to the future

The successes of Gilenya, Afinitor/Votubia, Galvus, Tasigna and Jakavi - as well as its generics arm, Sandoz - mean that Novartis is now less than $500m behind Pfizer in second place.
Pharma deals during April 2014

Novartis' pipeline includes more than 25 new molecular entities targeting key oncogenic pathways including: Gleevec and its follow-up Tasigna (blood-cancer); Afinitor (kidney cancer and recently approved for breast cancer);
Interview: Joseph Jimenez, Novartis

In 2010, we had 13 key product approvals and 16 major filings in pharma, including Gilenya, Lucentis and Afinitor," he points out. ... populations. "In Q2 alone, we had four major approvals and two major filings, including Afinitor, Arcapta Neohaler,

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Oncology drugs under AMNOG

patients the comparator was a different targeted therapy, Afinitor (everolimus), rather than Nexavar - although for cytokine-pretreated patients the trial comparator could be used.The G-BA still exercises its right

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Home based, Editorial Team Leader, Medical Communications: Excellent package

Home based, Senior Medical Writer, Medical Communications: Excellent package

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Home based, Principal Medical Writer, Medical Communications: Excellent package

Add my company

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....